文献速递妇科

月经过多的治疗方法的成本效益

Cost-effectiveness of treatments for heavy menstrual bleeding.
PubMed 文献 · Am J Obstet Gynecol · 2017-07-25

本研究采用决策树模型,评估子宫切除术、宫腔镜子宫内膜去除术、非宫腔镜子宫内膜去除术和左炔诺孕酮宫内缓释系统治疗月经过多的5年成本效益。结果显示,左炔诺孕酮宫内缓释系统在多数场景下(90%)相比子宫切除术具有成本效益,且生活质量更优。

要点

  • 左炔诺孕酮宫内缓释系统的生活质量结局优于子宫切除术且成本更低。
  • 概率敏感性分析中,左炔诺孕酮宫内缓释系统在90%的场景下相比子宫切除术具有成本效益。
  • 宫腔镜和非宫腔镜子宫内膜去除术成本低于子宫切除术但生活质量较低,分别有44%和53%场景具有成本效益。

核心结论

  • 在四种月经过多治疗方案的权衡比较中,左炔诺孕酮宫内缓释系统在成本和生活质量方面均优于子宫切除术和子宫内膜去除术。

研究设计与样本

  • 决策树模型评估私人支付方成本和5年时间范围内的质量调整生命年,对象为无恶性肿瘤可疑的绝经前月经过多女性。

主要发现

  • 左炔诺孕酮宫内缓释系统的生活质量结局优于子宫切除术且成本更低。
  • 概率敏感性分析中,左炔诺孕酮宫内缓释系统在多数场景(90%)下相比子宫切除术具有成本效益。
  • 宫腔镜子宫内膜去除术和非宫腔镜子宫内膜去除术成本低于子宫切除术但平均生活质量较低。
  • 按标准意愿支付阈值,宫腔镜子宫内膜去除术在44%场景下相比子宫切除术具有成本效益,非宫腔镜子宫内膜去除术在53%场景下具有成本效益。

临床怎么用

  • 对于不愿或不能选择左炔诺孕酮宫内缓释系统作为月经过多一线治疗的女性,可考虑成本、手术特定并发症和患者偏好来指导子宫切除术与子宫内膜去除术之间的决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heavy menstrual bleeding affects up to one third of women in the United States, resulting in a reduced quality of life and significant cost to the health care system. Multiple treatment options exist, offering different potential for symptom control at highly variable initial costs, but the relative value of these treatment options is unknown. OBJECTIVE: The objective of the study was to evaluate the relative cost-effectiveness of 4 treatment options for heavy menstrual bleeding: hysterectomy, resectoscopic endometrial ablation, nonresectoscopic endometrial ablation, and the levonorgestrel-releasing intrauterine system. STUDY DESIGN: We formulated a decision tree evaluating private payer costs and quality-adjusted life years over a 5 year time horizon for premenopausal women with heavy menstrual bleeding and no suspected malignancy. For each treatment option, we used probabilities derived from literature review to estimate frequencies of minor complications, major complications, and treatment failure resulting in the need for additional treatments. Treatments were compared in terms of total average costs, quality-adjusted life years, and incremental cost-effectiveness ratios. Probabilistic sensitivity analysis was conducted to understand the range of possible outcomes if model inputs were varied. RESULTS: The levonorgestrel-releasing intrauterine system had superior quality-of-life outcomes to hysterectomy with lower costs. In a probabilistic sensitivity analysis, levonorgestrel-releasing intrauterine system was cost-effective compared with hysterectomy in the majority of scenarios (90%). Both resectoscopic and nonresectoscopic endometrial ablation were associated with reduced costs compared with hysterectomy but resulted in a lower average quality of life. According to standard willingness-to-pay thresholds, resectoscopic endometrial ablation was considered cost effective compared with hysterectomy in 44% of scenarios, and nonresectoscopic endometrial ablation was considered cost effective compared with hysterectomy in 53% of scenarios. CONCLUSION: Comparing all trade-offs associated with 4 possible treatments of heavy menstrual bleeding, the levonorgestrel-releasing intrauterine system was superior to both hysterectomy and endometrial ablation in terms of cost and quality of life. Hysterectomy is associated with a superior quality of life and fewer complications than either type of ablation but at a higher cost. For women who are unwilling or unable to choose the levonorgestrel-releasing intrauterine system as a first-course treatment for heavy menstrual bleeding, consideration of cost, procedure-specific complications, and patient preferences can guide the decision between hysterectomy and ablation.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Spencer JC, Louie M, Moulder JK, et al. Cost-effectiveness of treatments for heavy menstrual bleeding. Am J Obstet Gynecol. 2017. PMID: 28754438. doi:10.1016/j.ajog.2017.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。